Platform
Home
Screener
Copilot
AskEdgar Studio
New
Back
Satellos Bioscience Inc.
MSLE · SEC Filings
website
18
Satellos Bioscience Inc., a biotechnology company, develops medicines to treat degenerative muscle d...
Price
7.49
Market Cap
9.65 M
Float
1.06 M
Country
CA
Sector
Healthcare
Exchange
NASDAQ
Overview
Filings
Insights
Dilution
News
Transcripts
Search in Documents
Open in Studio
Studio
Login
Ask about MSLE
TYPE
HEADLINE
FILED AT
TYPE
HEADLINE
FILED AT
TYPE
HEADLINE
FILED AT
TYPE
HEADLINE
FILED AT
All
Chronological
Financials
Registrations
Prospectus
News
Proxies
Ownerships
Other
Satellos Bioscience Inc.
MSLE · SEC Filings
1.06 M
Float
7.49
Price
9.65 M
Market Cap
Financials
TYPE
HEADLINE
FILED AT
40-F
Form 40-F - Registration statement [Section 12] or Annual Report [Section 13(a), 15(d)]
Mar 27, 2026
News
TYPE
HEADLINE
FILED AT
6-K
Satellos Changes Primary Efficacy Endpoint in BASECAMP Phase 2 Pediatric Trial to MRI-Measured Fat Fraction Following FDA Feedback
Nov 6, 2026
6-K
Satellos to Host Investor Call to Provide Update on Clinical and Regulatory Strategy for BASECAMP Phase 2 Pediatric Study
Nov 5, 2026
6-K
Satellos Establishes Scientific Advisory Board to Explore Regeneration in Aging and Neuroscience
Oct 27, 2026
6-K
Satellos Bioscience to Participate in November Investor Conferences and Highlights Clinical Progress
Oct 21, 2026
6-K
Satellos Granted Composition of Matter Patent for Forazapadin
Oct 5, 2026
6-K
Satellos Announces Completion of Enrollment in BASECAMP Phase 2 Clinical Trial of Forazapadin for Duchenne Muscular Dystrophy
Sep 30, 2026
Prospectus
TYPE
HEADLINE
FILED AT
Registrations
TYPE
HEADLINE
FILED AT
F-10
August 2026 SHELF
Aug 11, 2026
S-8
Form S-8 - Securities to be offered to employees in employee benefit plans
Mar 27, 2026
8-A12B
Form 8-A12B - Registration of securities [Section 12(b)]
Feb 5, 2026
F-10
February 2026 SHELF
Feb 5, 2026
D
Form D - Notice of Exempt Offering of Securities - Item 06b
Jan 3, 2025
D
Form D - Notice of Exempt Offering of Securities - Item 06b
May 25, 2023
Proxies
TYPE
HEADLINE
FILED AT
Ownerships
TYPE
HEADLINE
FILED AT
SCHEDULE 13G
Bloom Brian Matthew (Filed by)
May 15, 2026
SCHEDULE 13G
Qiming U.S. Healthcare Fund III, L.P. (Filed by)
May 12, 2026
Chronological
TYPE
HEADLINE
FILED AT
Other
TYPE
HEADLINE
FILED AT
